Research programme: TGF-beta RI kinase inhibitors - Scios

Drug Profile

Research programme: TGF-beta RI kinase inhibitors - Scios

Alternative Names: SX-007; TGF-beta RI kinase inhibitors; TGF-beta RI kinase inhibitors research programme - Scios

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Class
  • Mechanism of Action Transforming growth factor beta1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA
  • 09 May 2005 Preclinical trials in Glioblastoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top